A Phase 2 interventional study of X-82 and Anti-VEGF in Age-Related Macular Degeneration (AMD), Macular Degeneration and Exudative Age-related Macular Degeneration, sponsored by Tyrogenex. Terminated at 35 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2022-02-11.
Sponsored by Tyrogenex · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 645 studies in Macular Degeneration with a site in United States — 84 open to participants now, 128 under way, 24 of them phase 3. Macular Degeneration · United States.
Among the 645 studies in Macular Degeneration with a site in United States, this one is the 132nd largest by enrollment of the 491 interventional ones that give a count, is one of 32 that started in 2015, is one of 138 in phase 2, and was the 304th registered.
1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.
Browse Macular Degeneration studies →84 of the 645 studies in Macular Degeneration with a site in United States are open now. Recruiting first, the newest first:
Genentech, Inc. · Sites in United States
Ages 50+
Biojiva LLC · Sites in United States, Australia
Ages 55+
Sitala Bio LTD · Sites in United States, Argentina, Australia and 4 more countries
Ages 60+
Scott Raymond · Sites in United States
Ages 50–80
Astellas Institute for Regenerative Medicine · Sites in United States
Ages 6+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
645 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 152 · Phase 2 216 · Phase 3 103 · Phase 4 27
First in 1992; this study’s year is marked. 32 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 157 is above the median of 56 across 985 interventional studies indexed under Macular Degeneration.
Median enrollment 55 across the 491 interventional studies, 100 across the 146 observational. Of the 464 that completed or were terminated, 183 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
375 of 645 have an industry lead sponsor. The 10 most frequent:
Tyrogenex is the lead sponsor of 3 studies on the registry; none are open to participants now.
Tyrogenex has 1 study filed under Macular Degeneration — fewer than ten, so there is no comparison to draw.
36 of the studies in Macular Degeneration with a site in United States that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04704921Phase 3AbbViePivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD | 2026-12 |
| NCT06495918Phase 3Ocular Therapeutix, Inc.Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration | 2027-01-08 |
| NCT06864988Phase 34D Molecular Therapeutics4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration | 2027-06 |
| NCT05904028Phase 3Jaeb Center for Health ResearchHome OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD | 2027-07-30 |
| NCT07614776Phase 3AmgenA Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration | 2027-07-31 |
Add all 36 to your calendar (.ics) → With an account.
Among the 645 studies in Macular Degeneration with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and efficacy of X-82 in the treatment of vision loss due to wet AMD.
Subjects will be randomized in a 1:1:1:1 ratio to the following dose groups:
Subjects will be treated for a total of 52 weeks with one of three doses of X-82 or placebo.
Primary Efficacy Outcome:
The primary efficacy outcome is the change in visual acuity score from Day -1 to 52 Weeks after randomization.
Safety Outcomes:
Systemic and ocular safety will be evaluate by assessing ECG, laboratory analyses, adverse events and serious adverse events.
Approximately 132 subjects will be randomized into one of the four arms (33 subjects per dose group).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subject will administer one 50 mg tablet of X-82 and one placebo tablet once daily. Subjects will be assessed for the need for retreatment with ivt anti-VEGF therapy at each visit.
Drug: X-82 · Drug: Anti-VEGF
Subject will administer two 50 mg tablets of X-82 once daily. Subjects will be assessed for the need for retreatment with ivt anti-VEGF therapy at each visit.
Drug: X-82 · Drug: Anti-VEGF
Subject will administer two 100 mg tablets of X-82 once daily. Subjects will be assessed for the need for retreatment with ivt anti-VEGF therapy at each visit.
Drug: X-82 · Drug: Anti-VEGF
Subject will administer two placebo tablets once daily. Subjects will be assessed for the need for retreatment with ivt anti-VEGF therapy at each visit.
Drug: Anti-VEGF · Drug: Placebo
Mean Change in Visual Acuity Score From Day -1 to Week52
The primary outcome is the change in the visual acuity score from Day -1 to 52 weeks after randomization.
Time frame: Week 52
This study was conducted at 39 sites in the United States. There were 36 sites that screened subjects and 3 sites that did not screen any subjects. A total of 157 subjects were randomly assigned and treated in the study.
| Milestone | 50 mg of X-82 Plus Ivt Anti-VEGF Prn | 100 mg of X-82 Plus Ivt Anti-VEGF Prn | 200 mg of X-82 Plus Ivt Anti-VEGF Prn | Placebo Plus Ivt Anti-VEGF Prn |
|---|---|---|---|---|
| Started | 40 | 39 | 39 | 39 |
| Completed | 29 | 22 | 25 | 27 |
| Not completed | 11 | 17 | 14 | 12 |
The primary outcome is the change in the visual acuity score from Day -1 to 52 weeks after randomization.
| number of letters | 50 mg of X-82 Plus Ivt Anti-VEGF Prn | 100 mg of X-82 Plus Ivt Anti-VEGF Prn | 200 mg of X-82 Plus Ivt Anti-VEGF Prn | Placebo Plus Ivt Anti-VEGF Prn |
|---|---|---|---|---|
| Mean Change in Visual Acuity Score From Day -1 to Week52 | 0.2 ± 4.14 | -0.9 ± 6.57 | 1.7 ± 5.58 | -0.3 ± 10.63 |
Collected over All adverse events were collected and reported from time of participant study entry until discharge of last participant from the study. Individual subject participation in the study ranged from 0-14 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 50 mg of X-82 Plus Ivt Anti-VEGF Prn | 0/40 (0%) | 6/40 (15%) | 39/40 (97.5%) |
| 100 mg of X-82 Plus Ivt Anti-VEGF Prn | 1/39 (2.6%) | 7/39 (17.9%) | 38/39 (97.4%) |
| 200 mg of X-82 Plus Ivt Anti-VEGF Prn | 0/39 (0%) | 3/39 (7.7%) | 37/39 (94.9%) |
| Placebo Plus Ivt Anti-VEGF Prn | 0/39 (0%) | 2/39 (5.1%) | 34/39 (87.2%) |
| Event | 50 mg of X-82 Plus Ivt Anti-VEGF Prn | 100 mg of X-82 Plus Ivt Anti-VEGF Prn | 200 mg of X-82 Plus Ivt Anti-VEGF Prn | Placebo Plus Ivt Anti-VEGF Prn |
|---|---|---|---|---|
| lower gastrointestinal hemorrhageGastrointestinal disorders | 0/40 | 0/39 | 1/39 | 0/39 |
| Chest painGeneral disorders | 0/40 | 0/39 | 1/39 | 0/39 |
| sudden cardiac deathCardiac disorders | 0/40 | 1/39 | 0/39 | 0/39 |
| EndopthalmitisInfections and infestations | 0/40 | 1/39 | 0/39 | 0/39 |
| InfluenzaInfections and infestations | 0/40 | 1/39 | 0/39 | 0/39 |
| PneumoniaInfections and infestations | 0/40 | 0/39 | 0/39 | 1/39 |
| DehydrationMetabolism and nutrition disorders | 0/40 | 1/39 | 0/39 | 0/39 |
| HypokalemiaMetabolism and nutrition disorders | 0/40 | 1/39 | 0/39 | 0/39 |
| Bladder cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/40 | 1/39 | 0/39 | 0/39 |
| B cell lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/40 | 0/39 | 1/39 | 0/39 |
| Event | 50 mg of X-82 Plus Ivt Anti-VEGF Prn | 100 mg of X-82 Plus Ivt Anti-VEGF Prn | 200 mg of X-82 Plus Ivt Anti-VEGF Prn | Placebo Plus Ivt Anti-VEGF Prn |
|---|---|---|---|---|
| Hair color changeSkin and subcutaneous tissue disorders | 2/40 | 10/39 | 13/39 | 0/39 |
| Alanine aminotransferase increasedInvestigations | 8/40 | 11/39 | 9/39 | 2/39 |
| Aspartate aminotransferase increasedInvestigations | 6/40 | 10/39 | 8/39 | 1/39 |
| DysgeusiaNervous system disorders | 3/40 | 5/39 | 10/39 | 0/39 |
| DiarrhoeaGastrointestinal disorders | 1/40 | 4/39 | 9/39 | 2/39 |
| NasopharyngitisInfections and infestations | 7/40 | 2/39 | 5/39 | 2/39 |
| FatigueGeneral disorders | 2/40 | 4/39 | 6/39 | 0/39 |
| AlopeciaSkin and subcutaneous tissue disorders | 1/40 | 2/39 | 6/39 | 0/39 |
| nauseaGastrointestinal disorders | 6/40 | 2/39 | 1/39 | 1/39 |
| Urinary tract infectionInfections and infestations | 2/40 | 5/39 | 1/39 | 2/39 |
All randomized subjects
| Age, Continuous(years) | 50 mg of X-82 Plus Ivt Anti-VEGF Prn | 100 mg of X-82 Plus Ivt Anti-VEGF Prn | 200 mg of X-82 Plus Ivt Anti-VEGF Prn | Placebo Plus Ivt Anti-VEGF Prn | Total |
|---|---|---|---|---|---|
| Mean | 75.7 ± 8.23 | 73.5 ± 8.33 | 75.0 ± 7.63 | 75.9 ± 7.65 | 75.0 ± 7.95 |
| Sex: Female, Male(Participants) | 50 mg of X-82 Plus Ivt Anti-VEGF Prn | 100 mg of X-82 Plus Ivt Anti-VEGF Prn | 200 mg of X-82 Plus Ivt Anti-VEGF Prn | Placebo Plus Ivt Anti-VEGF Prn | Total |
|---|---|---|---|---|---|
| Female | 22 | 16 | 18 | 23 | 79 |
| Male | 18 | 23 | 21 | 16 | 78 |
| Race (NIH/OMB)(Participants) | 50 mg of X-82 Plus Ivt Anti-VEGF Prn | 100 mg of X-82 Plus Ivt Anti-VEGF Prn | 200 mg of X-82 Plus Ivt Anti-VEGF Prn | Placebo Plus Ivt Anti-VEGF Prn | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 40 | 38 | 38 | 38 | 154 |
| More than one race | 0 | 1 | 0 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | 50 mg of X-82 Plus Ivt Anti-VEGF Prn | 100 mg of X-82 Plus Ivt Anti-VEGF Prn | 200 mg of X-82 Plus Ivt Anti-VEGF Prn | Placebo Plus Ivt Anti-VEGF Prn | Total |
|---|---|---|---|---|---|
| United States | 40 | 39 | 39 | 39 | 157 |
| Best corrected visual acuity(Number of letters) | 50 mg of X-82 Plus Ivt Anti-VEGF Prn | 100 mg of X-82 Plus Ivt Anti-VEGF Prn | 200 mg of X-82 Plus Ivt Anti-VEGF Prn | Placebo Plus Ivt Anti-VEGF Prn | Total |
|---|---|---|---|---|---|
| Mean | 72.3 ± 9.41 | 71.2 ± 12.17 | 71.9 ± 13.17 | 68.8 ± 12.43 | 71.0 ± 11.83 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2015 to primary completion in Dec 2017, 32 months.
Results were first posted in Jun 2018, 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vorolanib
Tyrogenex